Analyst firms · Truist Securities · CORT
Truist Securities CORT price target and rating history
Corcept Therapeutics Incorporated (CORT) · Health Care
Truist Securities rates Corcept Therapeutics Incorporated (CORT) Buy with a $164 price target, as of its latest action on Aug 18, 2026. It has published 4 rating actions on CORT since January 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Truist Securities's $164 is 128% above that.
- Current rating
- Buy
- Price target
- $164
- Median target, all firms
- $72
- Actions on CORT
- 4
Truist Securities price target on CORT
Every Truist Securities rating on CORT
- Aug 18, 2026
- Nov 6, 2023
- Aug 1, 2022
- Jan 28, 2022
How other firms rate CORT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Buy | $164 | Aug 18, 2026 |
| Wolfe Research | Underperform | $50 | Jul 27, 2026 |
| UBS | Buy | $72 | May 13, 2026 |
Questions about Truist Securities and CORT
- What is Truist Securities's price target for CORT?
- Truist Securities's latest stated price target for Corcept Therapeutics Incorporated (CORT) is $164, from its action on Aug 18, 2026.
- What is Truist Securities's rating on CORT?
- Truist Securities rates CORT Buy, a bullish rating, as of Aug 18, 2026.
- When did Truist Securities last change its view on CORT?
- On Aug 18, 2026, Truist Securities resumes coverage at Buy, price target $164.
- How does Truist Securities's CORT target compare with other analysts?
- Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Truist Securities's $164 is 128% above that.
More CORT rating histories
All Truist Securities ratingsCORT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.